CMPS
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways plc (CMPS) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Profitability (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | C- (2.0) | F (0.7) | B- (3.0) | C+ (2.6) | C (2.2) |
| 2026-11-04 | C+ (2.5) | C- (1.9) | D- (0.7) | B- (3.0) | C+ (2.7) | C- (2.1) |
| 2026-10-28 | C+ (2.5) | D+ (1.8) | D- (0.7) | B+ (3.8) | C+ (2.7) | C (2.3) |
| 2026-10-21 | C+ (2.5) | D+ (1.8) | F (0.6) | B+ (3.7) | C+ (2.6) | C (2.3) |
| 2026-10-14 | C+ (2.5) | D+ (1.8) | F (0.6) | B+ (3.6) | C+ (2.6) | C (2.2) |